Pharming Group (NASDAQ:PHAR) Trading Down 3.5% - Should You Sell?

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report)'s stock price dropped 3.5% on Wednesday . The company traded as low as $10.39 and last traded at $10.22. Approximately 444 shares traded hands during mid-day trading, a decline of 93% from the average daily volume of 6,095 shares. The stock had previously closed at $10.59.

Analyst Ratings Changes

PHAR has been the topic of a number of research reports. HC Wainwright restated a "buy" rating and issued a $37.00 price objective on shares of Pharming Group in a research note on Thursday, March 20th. Oppenheimer increased their price objective on Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a research note on Friday, March 14th.

Pharming Group Price Performance

The company has a quick ratio of 2.00, a current ratio of 2.76 and a debt-to-equity ratio of 0.39. The firm has a market cap of $681.66 million, a PE ratio of -50.10 and a beta of 0.02. The firm's fifty day simple moving average is $10.48 and its two-hundred day simple moving average is $9.45.

Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.03. Pharming Group had a negative net margin of 4.14% and a negative return on equity of 6.01%. The business had revenue of $79.09 million for the quarter, compared to analysts' expectations of $67.74 million. As a group, research analysts expect that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 52,147 shares of the company's stock after buying an additional 4,150 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.08% of Pharming Group worth $557,000 at the end of the most recent quarter. 0.03% of the stock is owned by institutional investors and hedge funds.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.